Dr. Darryl Leong, MD

Claim this profile

Hamilton General Hospital

Studies Heart Failure
Studies Cancer
3 reported clinical trials
6 drugs studied

Area of expertise

1

Heart Failure

Darryl Leong, MD has run 2 trials for Heart Failure. Some of their research focus areas include:

Stage I
Stage II
Stage III
2

Cancer

Darryl Leong, MD has run 2 trials for Cancer.

Affiliated Hospitals

Image of trial facility.

Hamilton General Hospital

Image of trial facility.

McMaster University

Clinical Trials Darryl Leong, MD is currently running

Image of trial facility.

Stopping Heart Medications

for Cancer Survivors

Cancer therapy-related cardiac dysfunction (CTRCD) is when the heart's ability to pump oxygenated blood to the body is compromised. It is a side effect of cancer therapy which can occur as commonly as in 1 in 5 patients. When this occurs, heart failure medications are started to protect the heart from progressing to heart failure. With early detection and treatment, heart function recovers to normal in \>80% of patients. Unfortunately, heart failure medications are associated with an undesirable long-term pill burden, financial costs, and side-effects (e.g., dizziness and fatigue). As a result, cancer survivors frequently ask if they can safely stop their heart failure medications once their heart function has returned to normal. Currently there is no scientific evidence in this area of Cardio-Oncology. To address this knowledge gap, the investigators have designed a randomized control trial to assess the safety of stopping heart failure medication in patients with CTRCD and recovered heart function. The investigators will enrol patients who have completed their cancer therapy and are on heart medications for their CTRCD, which has now normalized. The investigators will randomize patients with no other reasons to continue heart failure medications (e.g., kidney disease) to continuing or stopping their heart medications safely. All patients will undergo a cardiac MRI at baseline, 1 and 5 years with safety assessments at 6-8 weeks, 6 months and 3 and 5 years. The investigators will determine if stopping medications is non-inferior to continuing medications by counting the numbers of patients who develop heart dysfunction by 1 year in each group.

Recruiting

3 awards

Phase 4

Image of trial facility.

Abatacept

for Myocarditis

This Trial tests if abatacept can reduce serious heart problems in patients with heart inflammation caused by cancer treatments. Abatacept calms the immune system by preventing certain immune cells from becoming fully active, reducing inflammation and damage. Abatacept has been approved by the US Food and Drug Administration for the treatment of rheumatoid arthritis, with or without methotrexate.

Recruiting

3 awards

Phase 3

11 criteria

More about Darryl Leong, MD

Clinical Trial Related

1 year of experience running clinical trials · Led 3 trials as a Principal Investigator · 3 Active Clinical Trials

Treatments Darryl Leong, MD has experience with

  • Pertuzumab
  • Trastuzumab
  • Trastuzumab Emtansine
  • Stopping Heart Failure Medication(s)
  • Abatacept
  • Placebo

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Darryl Leong, MD specialize in?

Is Darryl Leong, MD currently recruiting for clinical trials?

Are there any treatments that Darryl Leong, MD has studied deeply?

What is the best way to schedule an appointment with Darryl Leong, MD?

What is the office address of Darryl Leong, MD?

Is there any support for travel costs?